Operaciones Natera, Inc. - NTRA CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | - | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | N/A |
| Abrir* | N/A |
| Cambio de 1 año* | N/A |
| Rango del día* | N/A |
| Rango de 52 semanas | 27.35-59.75 |
| Volumen medio (10 días) | 1.15M |
| Volumen medio (3 meses) | 28.75M |
| Capitalización de mercado | 6.34B |
| Ratio P/E | -100.00K |
| Acciones en circulación | 113.29M |
| Ingresos | 820.22M |
| EPS | -5.57 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 1.20 |
| Próxima fecha de resultados | May 3, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|
Natera, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 820.222 | 625.486 | 391.005 | 302.328 | 257.654 |
| Ingresos | 820.222 | 625.486 | 391.005 | 302.328 | 257.654 |
| Coste de los ingresos, total | 456.256 | 318.418 | 203.62 | 175.47 | 166.055 |
| Beneficio bruto | 363.966 | 307.068 | 187.385 | 126.858 | 91.599 |
| Gastos totales de explotación | 1361.26 | 1093.66 | 613.13 | 418.615 | 372.282 |
| Gastos de venta/general/administración Gastos, total | 588.591 | 511.034 | 303.627 | 204.476 | 154.872 |
| Investigación y desarrollo | 316.415 | 264.208 | 100.035 | 51.357 | 51.355 |
| Ingresos de explotación | -541.04 | -468.174 | -222.125 | -116.287 | -114.628 |
| Ingresos por intereses (gastos), netos No operativos | -9.319 | -8.305 | -15.082 | -10.693 | -10.476 |
| Otros, netos | 3.538 | 5.381 | 7.562 | 4.152 | -2.729 |
| Ingresos netos antes de impuestos | -546.821 | -471.098 | -229.645 | -122.828 | -127.833 |
| Ingresos netos después de impuestos | -547.799 | -471.716 | -229.743 | -124.827 | -128.154 |
| Beneficio neto antes de partidas extra. Elementos | -547.799 | -471.716 | -229.743 | -124.827 | -128.154 |
| Ingresos netos | -547.799 | -471.716 | -229.743 | -124.827 | -128.154 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -547.799 | -471.716 | -229.743 | -124.827 | -128.154 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -547.799 | -471.716 | -229.743 | -124.827 | -128.154 |
| Beneficio neto diluido | -547.799 | -471.716 | -229.743 | -124.827 | -128.154 |
| Promedio ponderado de acciones diluidas | 98.408 | 90.558 | 81.011 | 69.555 | 57.848 |
| BPA diluido sin partidas extraordinarias | -5.56661 | -5.20899 | -2.83595 | -1.79465 | -2.21536 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| BPA normalizado diluido | -5.56661 | -5.20899 | -2.78903 | -1.91322 | -2.21536 |
| Total de partidas extraordinarias | |||||
| Gastos (ingresos) extraordinarios | 0 | 0 | 5.848 | -12.688 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Ingresos totales | 217.252 | 210.637 | 198.2 | 194.133 | 173.028 |
| Ingresos | 217.252 | 210.637 | 198.2 | 194.133 | 173.028 |
| Coste de los ingresos, total | 127.292 | 116.512 | 109.237 | 103.215 | 94.122 |
| Beneficio bruto | 89.96 | 94.125 | 88.963 | 90.918 | 78.906 |
| Gastos totales de explotación | 359.025 | 329.689 | 341.285 | 331.263 | 312.694 |
| Gastos de venta/general/administración Gastos, total | 143.822 | 147.667 | 149.468 | 147.634 | 146.761 |
| Investigación y desarrollo | 87.911 | 65.51 | 82.58 | 80.414 | 71.811 |
| Ingresos de explotación | -141.773 | -119.052 | -143.085 | -137.13 | -139.666 |
| Ingresos por intereses (gastos), netos No operativos | -2.752 | -2.33 | -2.15 | -2.087 | -2.079 |
| Otros, netos | 2.373 | 0.087 | 0.277 | 0.801 | 1.151 |
| Ingresos netos antes de impuestos | -142.152 | -121.295 | -144.958 | -138.416 | -140.594 |
| Ingresos netos después de impuestos | -142.573 | -121.48 | -145.151 | -138.595 | -140.564 |
| Beneficio neto antes de partidas extra. Elementos | -142.573 | -121.48 | -145.151 | -138.595 | -140.564 |
| Ingresos netos | -142.573 | -121.48 | -145.151 | -138.595 | -140.564 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -142.573 | -121.48 | -145.151 | -138.595 | -140.564 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -142.573 | -121.48 | -145.151 | -138.595 | -140.564 |
| Beneficio neto diluido | -142.573 | -121.48 | -145.151 | -138.595 | -140.564 |
| Promedio ponderado de acciones diluidas | 104.408 | 97.052 | 96.579 | 95.578 | 94.842 |
| BPA diluido sin partidas extraordinarias | -1.36554 | -1.2517 | -1.50293 | -1.45007 | -1.48209 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| BPA normalizado diluido | -1.36554 | -1.2517 | -1.50293 | -1.45007 | -1.48209 |
| Gastos (ingresos) extraordinarios | 0 | 0 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 1093.14 | 862.663 | 523.167 | 240.518 | 180.625 |
| Efectivo e inversiones a corto plazo | 914.282 | 737.274 | 440.991 | 153.868 | 118.867 |
| Efectivo y Equivalentes | 84.386 | 48.668 | 61.926 | 46.407 | 12.62 |
| Inversiones a corto plazo | 829.896 | 688.606 | 379.065 | 107.461 | 106.247 |
| Total deudores, neto | 122.074 | 78.565 | 53.351 | 62.223 | 44.089 |
| Accounts Receivable - Trade, Net | 122.074 | 78.565 | 53.351 | 62.223 | 44.089 |
| Total Inventory | 26.909 | 20.031 | 12.394 | 13.633 | 8.998 |
| Prepaid Expenses | 29.645 | 26.606 | 16.376 | 6.197 | 8.612 |
| Other Current Assets, Total | 0.228 | 0.187 | 0.055 | 4.597 | 0.059 |
| Total Assets | 1236.49 | 932.153 | 582.656 | 268.171 | 214.613 |
| Property/Plant/Equipment, Total - Net | 124.529 | 54.747 | 47.013 | 24.336 | 29.667 |
| Property/Plant/Equipment, Total - Gross | 143.942 | 104.801 | 88.537 | 58.633 | 56.652 |
| Accumulated Depreciation, Total | -19.413 | -50.054 | -41.524 | -34.297 | -26.985 |
| Other Long Term Assets, Total | 18.82 | 14.743 | 12.476 | 3.317 | 4.321 |
| Total Current Liabilities | 218.956 | 199.053 | 179.874 | 113.981 | 105.561 |
| Accounts Payable | 27.206 | 8.096 | 8.604 | 14.587 | 8.529 |
| Accrued Expenses | 114.854 | 71.689 | 54.03 | 33.843 | 35.558 |
| Notes Payable/Short Term Debt | 50.052 | 50.054 | 50.123 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 50.153 | 50.112 | |||
| Other Current Liabilities, Total | 26.844 | 69.214 | 67.117 | 15.398 | 11.362 |
| Total Liabilities | 583.183 | 445.917 | 303.945 | 236.009 | 189.196 |
| Total Long Term Debt | 280.394 | 202.493 | 73.656 | 73.357 | 73.065 |
| Other Liabilities, Total | 83.833 | 44.371 | 50.415 | 48.671 | 10.57 |
| Total Equity | 653.304 | 486.236 | 278.711 | 32.162 | 25.417 |
| Preferred Stock - Non Redeemable, Net | 0 | ||||
| Common Stock | 0.01 | 0.009 | 0.008 | 0.007 | 0.006 |
| Additional Paid-In Capital | 2050.42 | 1411.29 | 976.955 | 607.236 | 472.552 |
| Retained Earnings (Accumulated Deficit) | -1394.84 | -929.318 | -699.171 | -574.529 | -446.375 |
| Other Equity, Total | -2.287 | 4.259 | 0.919 | -0.552 | -0.766 |
| Total Liabilities & Shareholders’ Equity | 1236.49 | 932.153 | 582.656 | 268.171 | 214.613 |
| Total Common Shares Outstanding | 95.14 | 86.223 | 78.005 | 62.083 | 54.04 |
| Long Term Debt | 280.394 | 202.493 | 73.656 | 73.357 | 73.065 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 980.226 | 1093.14 | 1191.22 | 739.888 | 791.403 |
| Efectivo e inversiones a corto plazo | 751.958 | 914.282 | 1023.7 | 580.243 | 653.572 |
| Efectivo y Equivalentes | 158.298 | 84.386 | 95.103 | 62.811 | 65.126 |
| Inversiones a corto plazo | 593.66 | 829.896 | 928.596 | 517.432 | 588.446 |
| Total deudores, neto | 167.862 | 122.074 | 110.416 | 100.13 | 87.562 |
| Accounts Receivable - Trade, Net | 167.862 | 122.074 | 110.416 | 100.13 | 87.562 |
| Total Inventory | 25.048 | 26.909 | 28.022 | 28.409 | 23.676 |
| Prepaid Expenses | 35.13 | 29.645 | 28.858 | 30.878 | 26.43 |
| Other Current Assets, Total | 0.228 | 0.228 | 0.228 | 0.228 | 0.163 |
| Total Assets | 1144.66 | 1236.49 | 1311.37 | 849.956 | 893.512 |
| Property/Plant/Equipment, Total - Net | 142.762 | 124.529 | 106.949 | 97.221 | 89.703 |
| Property/Plant/Equipment, Total - Gross | 165.177 | 143.942 | 165.263 | 152.538 | 142.306 |
| Accumulated Depreciation, Total | -22.415 | -19.413 | -58.314 | -55.317 | -52.603 |
| Other Long Term Assets, Total | 21.676 | 18.82 | 13.202 | 12.847 | 12.406 |
| Total Current Liabilities | 231.072 | 218.956 | 199.714 | 197.988 | 166.969 |
| Accounts Payable | 18.07 | 27.206 | 8.181 | 20.307 | 4.682 |
| Accrued Expenses | 130.919 | 114.854 | 114.18 | 93.183 | 81.711 |
| Notes Payable/Short Term Debt | 50.055 | 50.052 | 50.049 | 50.049 | 50.052 |
| Other Current Liabilities, Total | 32.028 | 26.844 | 27.304 | 34.449 | 30.524 |
| Total Liabilities | 602.329 | 583.183 | 552.357 | 550.846 | 521.067 |
| Total Long Term Debt | 280.706 | 280.394 | 280.085 | 279.777 | 279.471 |
| Long Term Debt | 280.706 | 280.394 | 280.085 | 279.777 | 279.471 |
| Other Liabilities, Total | 90.551 | 83.833 | 72.558 | 73.081 | 74.627 |
| Total Equity | 542.335 | 653.304 | 759.017 | 299.11 | 372.445 |
| Common Stock | 0.01 | 0.01 | 0.01 | 0.009 | 0.009 |
| Additional Paid-In Capital | 2089.66 | 2050.42 | 2011.79 | 1399.66 | 1356.21 |
| Retained Earnings (Accumulated Deficit) | -1533.43 | -1394.84 | -1254.27 | -1103 | -986.973 |
| Other Equity, Total | -13.904 | -2.287 | 1.491 | 2.441 | 3.197 |
| Total Liabilities & Shareholders’ Equity | 1144.66 | 1236.49 | 1311.37 | 849.956 | 893.512 |
| Total Common Shares Outstanding | 96.259 | 95.14 | 94.538 | 88.498 | 87.43 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -471.716 | -229.743 | -124.827 | -128.154 | -137.628 |
| Efectivo de actividades de explotación | -335.236 | -182.512 | -63.444 | -70.581 | -97.825 |
| Efectivo de actividades de explotación | 11.254 | 8.613 | 7.73 | 7.501 | 7.143 |
| Partidas no monetarias | 171.299 | 77.748 | 26.452 | 22.916 | 13.05 |
| Cash Taxes Paid | 0.283 | 0.067 | 2.154 | 0.332 | 0.177 |
| Intereses pagados en efectivo | 7.077 | 3.296 | 12.455 | 7.914 | 3.568 |
| Cambios en el capital circulante | -46.073 | -39.13 | 27.201 | 27.156 | 19.61 |
| Efectivo de actividades de inversión | -205.193 | -331.461 | -266.353 | -5.161 | 13.784 |
| Gastos de capital | -49.588 | -19.604 | -4.968 | -3.88 | -9.867 |
| Otras partidas de flujo de caja de inversión, total | -155.605 | -311.857 | -261.385 | -1.281 | 23.651 |
| Efectivo procedente de actividades de financiación | 576.188 | 500.847 | 340.774 | 113.725 | 80.372 |
| Emisión (retiro) de acciones, neto | 576.188 | 301.288 | 340.774 | 113.725 | 5.659 |
| Emisión (amortización) de deuda, neta | 0 | 199.559 | 0 | 0 | 75 |
| Variación neta de la tesorería | 35.759 | -13.126 | 10.977 | 37.983 | -3.669 |
| Elementos de flujo de caja de financiación | 0 | -0.287 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -138.595 | -471.716 | -331.152 | -179.879 | -63.853 |
| Cash From Operating Activities | -137.277 | -335.236 | -236.5 | -145.439 | -74.876 |
| Cash From Operating Activities | 3.002 | 11.254 | 8.259 | 5.262 | 2.549 |
| Non-Cash Items | 40.865 | 171.299 | 136.312 | 68.849 | 28.676 |
| Cash Interest Paid | 0.159 | 7.077 | 3.69 | 3.538 | 0.152 |
| Changes in Working Capital | -42.549 | -46.073 | -49.919 | -39.671 | -42.248 |
| Cash From Investing Activities | 207.033 | -205.193 | -284.697 | 146.709 | 86.74 |
| Capital Expenditures | -15.885 | -49.588 | -36.298 | -18.891 | -10.26 |
| Other Investing Cash Flow Items, Total | 222.918 | -155.605 | -248.399 | 165.6 | 97 |
| Cash From Financing Activities | 4.156 | 576.188 | 567.673 | 12.914 | 4.57 |
| Issuance (Retirement) of Stock, Net | 4.156 | 576.188 | 567.673 | 12.914 | 4.57 |
| Net Change in Cash | 73.912 | 35.759 | 46.476 | 14.184 | 16.434 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.7594 | 9923131 | 1628200 | 2022-12-31 | LOW |
| Fred Alger Management, LLC | Investment Advisor/Hedge Fund | 7.9205 | 8972823 | 191477 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2045 | 4763130 | 715214 | 2022-12-31 | LOW |
| Samlyn Capital, LLC | Hedge Fund | 3.8755 | 4390372 | 2113236 | 2022-12-31 | HIGH |
| JP Morgan Asset Management | Investment Advisor | 3.739 | 4235761 | 101390 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.1533 | 3572262 | 764812 | 2022-12-31 | LOW |
| Sofinnova Investments, Inc | Venture Capital | 2.7369 | 3100560 | -2400 | 2022-12-31 | MED |
| Citadel Advisors LLC | Hedge Fund | 2.6914 | 3048948 | 884865 | 2022-12-31 | HIGH |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.4544 | 2780428 | 1886903 | 2022-12-31 | LOW |
| Eversept Partners, LP | Hedge Fund | 2.371 | 2685959 | 1260357 | 2022-12-31 | MED |
| RTW Investments L.P. | Investment Advisor/Hedge Fund | 2.3033 | 2609283 | 400000 | 2022-12-31 | LOW |
| Kynam Capital Management LP | Hedge Fund | 2.2979 | 2603207 | 584847 | 2022-12-31 | HIGH |
| Principal Global Investors (Equity) | Investment Advisor | 1.7724 | 2007860 | 867205 | 2022-12-31 | LOW |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 1.7181 | 1946353 | 441200 | 2022-12-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 1.5879 | 1798900 | 63900 | 2022-12-31 | HIGH |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.5711 | 1779828 | 184128 | 2022-12-31 | LOW |
| Braidwell LP | Hedge Fund | 1.4309 | 1621012 | 1621012 | 2022-12-31 | |
| D. E. Shaw & Co., L.P. | Hedge Fund | 1.3493 | 1528566 | -53493 | 2022-12-31 | MED |
| Marshall Wace LLP | Investment Advisor/Hedge Fund | 1.3171 | 1492125 | 262940 | 2022-12-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3059 | 1479376 | 217067 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Natera, Inc. Company profile
Sobre Natera Inc
Natera, Inc. es una empresa de diagnóstico. La empresa se centra en el desarrollo y la comercialización de servicios de pruebas moleculares, aplicando su tecnología en los campos de la salud de la mujer, la oncología y la salud de los órganos. La tecnología de ADN libre de células (cfDNA) de la empresa combina sus ensayos moleculares, que miden de forma fiable muchas regiones informativas del genoma a partir de muestras tan pequeñas como una sola célula. La oferta de productos de la empresa incluye las pruebas prenatales no invasivas Panorama (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) y Prospera. La empresa también ofrece Constellation, una plataforma de software basada en la nube que permite a los clientes de los laboratorios acceder a través de la nube a los algoritmos y la bioinformática de la empresa para validar y lanzar pruebas basadas en la tecnología de la empresa.
| Industry: | Laboratory Diagnostic & Testing Substances |
13011 Mccallen Pass
Building A Suite 100
AUSTIN
TEXAS 78753
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com